Urology Times Highlights Research Presented by Dr. Abigail Keller at the American Urological Association 2026 Annual Meeting

Urology Times highlighted research presented by Abigail Keller, MD, Clinical Research Assistant with the Department of Urology at the Fox Chase – Temple Urologic Institute, during the American Urological Association (AUA) 2026 Annual Meeting that found nadofaragene firadenovec (NF), an intravesical gene therapy approved for the treatment of Bacillus Calmette–Guérin unresponsive non–muscle invasive bladder cancer, is associated with increased urine production during instillation compared with gemcitabine/docetaxel. The study suggests a diuretic phenomenon observed in patients associated with NF, which has yet to be reported.